🏛️ Verified NIH Record • Updated 2026-03-17

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT04699188)

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

Who can join: Review the eligibility criteria below.

Location: Emory University School of Medicine-Winship Cancer Institute — Atlanta, Georgia

Age range: 18 Years to 100 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

  • Emory University School of Medicine-Winship Cancer Institute — Atlanta, Georgia
  • Massachusetts General Hospital Cancer Center — Boston, Massachusetts
  • Massachusetts General Hospital — Boston, Massachusetts
  • Hillman Cancer Center — Pittsburgh, Pennsylvania
  • Uni Of TX MD Anderson Cancer Cntr — Houston, Texas
  • Novartis Investigative Site — Melbourne, Victoria
  • Novartis Investigative Site — Leuven,
  • Novartis Investigative Site — Montreal, Quebec
  • Novartis Investigative Site — Guangzhou, Guangdong
  • Novartis Investigative Site — Beijing,
  • Novartis Investigative Site — Copenhagen,
  • Novartis Investigative Site — Lyon,
  • Novartis Investigative Site — Marseille,
  • Novartis Investigative Site — Villejuif,
  • Novartis Investigative Site — Freiburg im Breisgau, Baden-Wurttemberg
  • Novartis Investigative Site — Cologne, North Rhine-Westphalia
  • Novartis Investigative Site — Dresden, Saxony
  • Novartis Investigative Site — Essen,
  • Novartis Investigative Site — Hong Kong,
  • Novartis Investigative Site — Brescia, BS
  • Novartis Investigative Site — Milan, MI
  • Novartis Investigative Site — Milan, MI
  • Novartis Investigative Site — Nagoya, Aichi-ken
  • Novartis Investigative Site — Kashiwa, Chiba
  • Novartis Investigative Site — Osaka, Osaka

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in KRAS G12C Mutant Solid Tumors

Explore by condition: All KRAS G12C Mutant Solid Tumors clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗